Autopsy report · NCT05226533

Clinical Trials to Assess Safety and Efficacy of DWRX2003 Combination With Remdesivir in Moderate to Severe COVID-19 Patients.

“Study stopped due to difficulties in patient recruitment”

The sponsor’s own words in the registry.

Life of this trial

• Registered 2 months before it started.
• Ran for about 9 months before it stopped.
• 1 participant enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Daewoong Pharmaceutical Co. LTD.

Sponsor type

Industry

Conditions

COVID-19

Interventions

DWRX2003; Placebo

Participants

1

Sites

3

Countries

Indonesia

Trials that died the same way

• All-On-4® Treatment Concept
  “The study stopped as the performance of the study showed insufficient patient recruitment.” (89% match in meaning)
• Exercise to Prevent Aromatase Inhibitor Side Effects in Breast Cancer Patients
  “The study was stopped due to recruitment difficulties” (86% match in meaning)
• Fondaparinux 1,5 mg for the Prevention of Venous Thromboembolism (VTE) in Medical Patients With Renal Insufficiency
  “study was stopped after enrolment of about 200 patients for slow recruitment” (86% match in meaning)
• Effect of Rufinamide on Chronic Postthoracotomy Pain Syndrome
  “Poor study patient recruitment” (85% match in meaning)
• Efficacy of EndoClot™ Spraying After Endoscopic Resection of Large Colorectal Polyps
  “insufficient recruitment of study patients” (83% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.